Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra

Benzinga · 3d ago

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).